{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:49:07Z","timestamp":1793638147866,"version":"4.5.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejps.2022.106155","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T20:49:21Z","timestamp":1646254161000},"page":"106155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-3985","authenticated-orcid":false,"given":"Hilmar","family":"Schiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Schuhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Drollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Woessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5382-7296","authenticated-orcid":false,"given":"Peter","family":"End","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2022.106155_bib0002","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cpt.384","article-title":"Teratogenic drugs and their drug interactions with hormonal contraceptives","volume":"100","author":"Ahn","year":"2016","journal-title":"Clinical pharmacology and therapeutics"},{"key":"10.1016\/j.ejps.2022.106155_bib0003","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejps.2022.106155_bib0004","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.contraception.2016.12.007","article-title":"Estimating systemic exposure to levonorgestrel from an oral contraceptive","volume":"95","author":"Basaraba","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.ejps.2022.106155_bib0005","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ejps.2022.106155_bib0001","first-page":"1","article-title":"Update on overall prevalence of major birth defects","volume":"57","year":"2008","journal-title":"MMWR. Morbidity and mortality weekly report"},{"key":"10.1016\/j.ejps.2022.106155_bib0006","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expert Rev Clin Immu"},{"key":"10.1016\/j.ejps.2022.106155_bib0007","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-014-1675-0","article-title":"Comparison of two endogenous biomarkers of CYP3A4 activity in a drug\u2013drug interaction study between midostaurin and rifampicin","volume":"70","author":"Dutreix","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejps.2022.106155_bib0009","article-title":"Evaluating the Risks of Drug Exposure in Human Pregnancies","year":"2005","journal-title":"Center for Drug Evaluation and Research (CDER)"},{"issue":"1","key":"10.1016\/j.ejps.2022.106155_bib24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/cts.13126","article-title":"Novel Bruton\u2019s Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling","volume":"15","author":"Huth","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejps.2022.106155_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejps.2022.106155_bib0012","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2017.06.001","article-title":"Bruton's tyrosine kinase (BTK) as a promising target in solid tumors","volume":"58","author":"Molina-Cerrillo","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejps.2022.106155_bib0013","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ejps.2022.106155_bib0014","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejps.2022.106155_bib0015","first-page":"205","article-title":"Sex-based differences in autoimmune diseases","volume":"52","author":"Ortona","year":"2016","journal-title":"Ann Ist Super Sanita"},{"key":"10.1016\/j.ejps.2022.106155_bib0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4196\/kjpp.2017.21.1.107","article-title":"Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin","volume":"21","author":"Park","year":"2017","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.ejps.2022.106155_bib0017","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1021\/acsmedchemlett.9b00317","article-title":"Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation","volume":"10","author":"Pulz","year":"2019","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.ejps.2022.106155_bib0018","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2133\/dmpk.DMPK-10-RV-094","article-title":"Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions","volume":"26","author":"Shitara","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ejps.2022.106155_bib0019","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","article-title":"Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells","volume":"152","author":"Smith","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.ejps.2022.106155_bib0020","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejps.2022.106155_bib0021","first-page":"1","article-title":"Selected practice recommendations for contraceptive use","year":"2016","journal-title":"World Health Organization"},{"key":"10.1016\/j.ejps.2022.106155_bib0022","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1021\/jm301302s","article-title":"Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling","volume":"56","author":"Wittwer","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejps.2022.106155_bib0023","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1124\/dmd.111.040162","article-title":"Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics","volume":"39","author":"Zamek-Gliszczynski","year":"2011","journal-title":"Drug Metab Dispos"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722000409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722000409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:03:30Z","timestamp":1760529810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098722000409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":22,"alternative-id":["S0928098722000409"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106155","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Novartis Pharma AG, Basel, Switzerland. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106155"}}